The study points out that Drp1 could serve as both a marker for the progression from steatosis to NASH and for the increasing stages of fibrosis, as well as a potent indicator of Kupffer cell infiltration in the liver, indicating that Drp1 could be a valuable therapeutic target for the treatment of NASH and liver fibrosis. This evidence concerns the gene DNM1L and metabolic dysfunction-associated steatohepatitis.